eXIthera Pharmaceuticals is a private, clinical stage biotech company developing small molecule Factor XIa inhibitors, which offer the potential of thrombosis prevention without the bleeding liabilities which exist for all current anticoagulation treatment options.

eXIthera’s lead intravenous (IV) candidate, frunexian (EP-7041), is a novel, potent and selective, short acting, small-molecule Factor XIa inhibitor. Frunexian is developed as anticoagulation treatment for various extracorporeal circulation conditions such as ECMO, CABG and dialysis.

eXIthera signed a strategic collaboration with Haisco Pharmaceutical Group for the development and commercialization of frunexian in China.